@article {Verma2020.12.15.20248199, author = {Amol A. Verma and Tejasvi Hora and Hae Young Jung and Michael Fralick and Sarah L. Malecki and Lauren Lapointe-Shaw and Adina Weinerman and Terence Tang and Janice L. Kwan and Jessica J. Liu and Shail Rawal and Timothy C.Y. Chan and Angela M. Cheung and Laura C. Rosella and Marzyeh Ghassemi and Margaret Herridge and Muhammad Mamdani and Fahad Razak}, title = {Patient characteristics, clinical care, resource use, and outcomes associated with hospitalization for COVID-19 in the Toronto area}, elocation-id = {2020.12.15.20248199}, year = {2020}, doi = {10.1101/2020.12.15.20248199}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Patient characteristics, clinical care, resource use, and outcomes associated with hospitalization for coronavirus disease (COVID-19) in Canada are not well described.Methods We described all adult discharges from inpatient medical services and medical-surgical intensive care units (ICU) between November 1, 2019 and June 30, 2020 at 7 hospitals in Toronto and Mississauga, Ontario. We compared patients hospitalized with COVID-19, influenza and all other conditions using multivariable regression models controlling for patient age, sex, comorbidity, and residence in long-term-care.Results There were 43,462 discharges in the study period, including 1,027 (3.0\%) with COVID-19 and 783 (2.3\%) with influenza. Patients with COVID-19 had similar age to patients with influenza and other conditions (median age 65 years vs. 68 years and 68 years, respectively, SD\<0.1). Patients with COVID-19 were more likely to be male (59.1\%) and 11.7\% were long-term care residents. Patients younger than 50 years accounted for 21.2\% of all admissions for COVID-19 and 24.0\% of ICU admissions. Compared to influenza, patients with COVID-19 had significantly greater mortality (unadjusted 19.9\% vs 6.1\%, aRR: 3.47, 95\%CI: 2.57, 4.67), ICU use (unadjusted 26.4\% vs 18.0\%, aRR 1.52, 95\%CI: 1.27, 1.83) and hospital length-of-stay (unadjusted median 8.7 days vs 4.8 days, aRR: 1.40, 95\%CI: 1.20, 1.64), and not significantly different 30-day readmission (unadjusted 8.6\% vs 8.2\%, aRR: 1.01, 95\%CI: 0.72, 1.42).Interpretation Adults hospitalized with COVID-19 during the first wave of the pandemic used substantial hospital resources and suffered high mortality. COVID-19 was associated with significantly greater mortality, ICU use, and hospital length-of-stay than influenza.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by CIHR Grant VR4-172743. The development of the GEMINI data platform has been supported with funding from the Canadian Cancer Society, the Canadian Frailty Network, the Canadian Institutes of Health Research, the Canadian Medical Protective Association, Green Shield Canada Foundation, the Natural Sciences and Engineering Research Council of Canada, Ontario Health, the St. Michaels Hospital Association Innovation Fund, the University of Toronto Department of Medicine, and in-kind support from partner hospitals and Vector Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board approval was obtained from all participating hospitals. REB approval for University Health Network (Toronto), Sunnybrook Health Sciences Centre (Toronto), and St. Michael{\textquoteright}s Hospital (Toronto) was obtained through the integrated Clinical Trials Ontario platform, with St. Michael{\textquoteright}s Hospital as the "Board of Record". REB approval was also obtained from Trillium Health Partners (Mississauga) and Mount Sinai Hospital (Toronto).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this manuscript are available from the investigators upon reasonable request, and within the constraints placed by local REB approvals and data sharing agreements.}, URL = {https://www.medrxiv.org/content/early/2020/12/16/2020.12.15.20248199}, eprint = {https://www.medrxiv.org/content/early/2020/12/16/2020.12.15.20248199.full.pdf}, journal = {medRxiv} }